Press Releases CSPC Pharmaceutical Group Ltd.

Equities

1093

HK1093012172

Delayed Hong Kong S.E. Other stock markets 07:14:47 06/05/2024 am IST			5-day change	1st Jan Change
6.69 ^HKD	-1.04%		+1.82%	-7.44%

26/04	CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor Obtains Clinical Trial Approval in the U.S	CI
24/04	CSPC Pharmaceutical's EBT Buys 8.5 Million Shares	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business Achievements	16/23/16	AQ
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update	01/23/01	AQ
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "OSELTAMIVIR PHOSPHATE CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL	01/21/01	PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "ALOGLIPTIN BENZOATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL	12/21/12	PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "SORAFENIB TOSYLATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL	12/21/12	PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR "DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION"	12/21/12	PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "SITAGLIPTIN PHOSPHATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL	12/21/12	PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL FIRST-IN-CLASS PRODUCT SYSA1801 GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA	07/21/07	PU
CSPC Pharmaceutical : CONNECTED TRANSACTION - DISPOSAL OF 49.5% EQUITY INTEREST IN JOINT VENTURE COMPANY /CONTINUING CONNECTED TRANSACTIONS - MASTER PURCHASE AGREEMENT	30/21/30	PU
CSPC Pharmaceutical : INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2021	26/21/26	PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - NBL-012 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA	23/21/23	PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - APPLICATION FOR MARKETING APPROVAL OF "DUVELISIB CAPSULES" ACCEPTED BY NMPA	20/21/20	PU
PROXY FORM FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, 18 MAY 2021 AT 10:00 A.M. (AND AT ANY ADJOURNMENT THEREOF)	14/21/14	PU
CSPC Pharmaceutical : PROPOSALS FOR GENERAL MANDATES TO BUY-BACK SHARES AND TO ISSUE SHARES AND MANDATE TO GRANT OPTIONS, RE-ELECTION OF THE RETIRING DIRECTORS, AND NOTICE OF ANNUAL GENERAL MEETING	14/21/14	PU
CSPC Pharmaceutical : INVESTIGATIONAL NEW DRUG NBL-015 GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA	09/21/09	PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL	01/21/01	PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF "DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)"	30/21/30	PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.	29/21/29	PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA	25/21/25	PU
CSPC Pharmaceutical : ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020	15/21/15	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CSPC Pharmaceutical Group Ltd.

Equities

1093

HK1093012172

Press Releases

Filters